Angle PLC MD Anderson Cancer Center poster presentation
August 04 2016 - 2:01AM
RNS Non-Regulatory
TIDMAGL
Angle PLC
04 August 2016
For immediate release 4 August 2016
ANGLE plc ("the Company")
MD ANDERSON CANCER CENTER DEMONSTRATES CLINICAL APPLICABILITY OF
ANGLE'S "BLOOD BIOPSY" TECHNOLOGY
Poster presentation at AACC shows harvest of breast cancer cells
in blood
using Parsortix(TM) cell separation system enables subsequent
gene expression analysis
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company,
announces a poster presentation by researchers from the University
of Texas MD Anderson Cancer Center describing clinically-relevant
results from a study using its lead product, the Parsortix cell
separation system, to harvest breast cancer cells in blood for
subsequent molecular characterisation. The poster was presented at
the American Association for Clinical Chemistry Annual Meeting on 2
August 2016.
The research team, led by Dr James M. Reuben, Professor,
Department of Hematopathology, MD Anderson Cancer Center, confirmed
the ability to perform advanced molecular analysis on breast cancer
cells isolated from blood samples using the Parsortix liquid biopsy
technology. The researchers note the ability of the Parsortix
method to harvest circulating tumor cells (CTCs) without the use of
antibodies.
In the study, entitled "Antibody-free microfluidics-based
circulating tumor cell enrichment by ANGLE plc Parsortix and
downstream molecular characterization by Affymetrix branched DNA
technology", the researchers describe the advantages of being able
to perform gene expression analysis on the harvested cells.
Following capture of breast cancer cells that were spiked into
healthy donor blood samples, the researchers measured the
expression of several genes, including specific breast-cancer
related genes. The study results show high specificity for
detection of the targeted genes and strong sensitivity for highly
expressed genes in dilutions of the harvested cell extracts. The
ability to measure gene expression in CTCs has the potential to
provide more clinically actionable information than simple
detection or quantification of tumor cells in blood.
This new research demonstrates the potential to obtain
particularly detailed information from CTCs regarding the cells
being analysed. Liquid biopsy using the Parsortix system, combined
with molecular characterisation of the CTCs, can be repeated over
time without requiring surgical removal of a tumor sample. It
offers a less invasive and more personalized approach to monitoring
for response to therapy and disease progression.
ANGLE Chief Technology Officer, Dr Shane Booth, commented:
"Multiplexed gene expression analysis will be a very important
approach in enabling new clinical diagnostic capability in oncology
through liquid biopsy. But this is technically demanding, and
leading edge techniques will need to be applied with CTCs if liquid
biopsy is to be robust and versatile. CTC analysis using array
based methods is an area of particular interest to us, and this
research is an important step in proving their efficacy with our
cell separation system, and in developing the required methodology.
Coming as they do from the renowned MD Anderson Cancer Center,
these developments and conclusions are encouraging and
exciting."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser)
Russell Kerr, Oliver Baxendale
(Sales) 020 7397 8900
WG Partners
David Wilson
Claes Spång 020 3705 9330
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberley Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China and
Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFELTSIVIIR
(END) Dow Jones Newswires
August 04, 2016 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024